Carlyle hires ex-Johnson & Johnson chair to advise Asia buyout

Wu also served as the global chairman of Johnson & Johnson's Consumer Group and has 30 years of experience in healthcare and related sectors. According to a statement, this background is expected to add healthcare expertise to Carlyle's buyout operations in Asia Pacific, which currently account for more than $1.3 billion of equity investments across seven companies in the region ex-Japan.

The appointment follows quickly on the promotion of David Bluff to managing director and head of Carlyle's Australia-New Zealand buyout team. Bluff also had experience in healthcare deal making, having participated in investments such as Healthscope, which the firm exited last year via an underwritten block trade believed to be worth A$853.7 million ($637.6 million).

Other recent healthcare activity by Carlyle in the region has included the acquisition of minority stakes in India's Metropolis Healthcare and China's Zhongmei Healthcare, which filed for a Hong Kong IPO earlier this year. The firm's Carlyle Asia Partners IV fund closed in 2014 at $3.9 billion with an aim to make control and significant minority investments across Asia ex-Japan.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Save this article  
• Send to  

• Topics
• Greater China
• Australasia
• People
• Buyout
• Healthcare
• South Asia
• The Carlyle Group
• Appointments